Related Experiment Video
Updated: Aug 2, 2025
Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells
Zhilan Zhou1, Ya Wang2, Zhengtao Shao2
1Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, 300072, China; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Abstract:
Drug resistance is a worldwide health care crisis which impedes disease treatment and increases financial burden, especially for its multifactorial nature and high complexity. Herein, we developed a multiparametric approach to visualize and detect drug resistance in living cancer cells, through the combination of DNA-templated covalent protein labeling strategy and fluorescent resonance energy transfer technique. Gefitinib resistance in non-small cell lung cancer caused by mesenchymal-epidermal transition factor (Met) overexpression and hyperactivation was investigated as a proof-of-concept. Unlike the traditional single-factor investigation, the proposed approach evaluated the contribution of three important parameters towards the resistance, including the changes of Met expression level, the homodimerization of Met with itself and the heterodimerization of Met with epidermal growth factor receptor (EGFR). A multiple regression model based on these three parameters was tentatively established for evaluation of the resistance level of laboratory-developed resistant cells and evaluation of the resistance level of patient-derived cells. Such an approach facilitates a quick identification of a drug resistance, to evaluate not only the resistance level but also the resistance mechanism.
Insights
A new multiparametric approach detects drug resistance in cancer cells by analyzing Met expression and dimerization. This method aids in identifying resistance levels and mechanisms, addressing a critical healthcare challenge.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Drug resistance poses a significant global health challenge, complicating cancer treatment and increasing costs.
- Current methods often focus on single factors, limiting a comprehensive understanding of complex drug resistance.
- Mesenchymal-epithelial transition factor (Met) signaling is implicated in gefitinib resistance in non-small cell lung cancer.
Purpose of the Study:
- To develop and validate a multiparametric approach for visualizing and detecting drug resistance in living cancer cells.
- To investigate gefitinib resistance in non-small cell lung cancer by assessing Met expression and dimerization.
- To establish a predictive model for evaluating drug resistance levels and mechanisms.
Main Methods:
- Utilized a DNA-templated covalent protein labeling strategy combined with Förster Resonance Energy Transfer (FRET).
- Quantified Met expression levels, Met homodimerization, and Met-EGFR heterodimerization.
- Developed a multiple regression model incorporating these parameters to assess resistance.
Main Results:
- Successfully visualized and detected drug resistance in living cancer cells using the developed approach.
- Evaluated the contribution of Met expression, Met homodimerization, and Met-EGFR heterodimerization to gefitinib resistance.
- The multiple regression model showed potential for evaluating resistance in both laboratory and patient-derived cells.
Conclusions:
- The multiparametric approach offers a comprehensive method for identifying drug resistance and its underlying mechanisms.
- This technique facilitates rapid assessment of resistance levels, moving beyond single-factor analyses.
- The findings have implications for improving cancer treatment strategies by better understanding drug resistance.
